Response

Authors:

Abstract
We appreciate the comments of Donna Graham et al. on our recent article ( 1 ). The first issue they raise concerns the use of an adjuvant treated patient cohort for risk scores intended to assist in decisions regarding whether or not such treatment should be administered at all. While we agree with this perception, we also contend that prognostic signatures so far have failed to provide information on likelihood of response to drugs in the adjuvant setting, which implies that they represent inherent prognostic groups, the outcome of which is not improved by therapy. This is an issue in itself, but beyond the scope of our paper. In absence of such evidence, a treated patient cohort is potentially as informative on the prognostic groups.
Keywords